Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 3, 2011, Pages 306-317

  Kamm, M A ^a,b   Hanauer, S B ^c   Panaccione, R ^d   Colombel, J F ^e   Sandborn, W J ^f   Pollack, P F ^g   Zhou, Q ^g   Robinson, A M ^g  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; BUDESONIDE; CORTICOSTEROID; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROHN DISEASE; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE PAIN; LOW DRUG DOSE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OPEN STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959952608     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04717.x     Document Type: Article

References (44)

1. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 935-9. (Pubitemid 43374542)
2. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66. (Pubitemid 14218578)
3. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
4. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69. (Pubitemid 9242048)
5. Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102: 1647-53.
6. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003; 4: CD000301.
7. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-8.
8. Markowitz JF,. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease. Rev Gastroenterol Disord 2003; 3 (Suppl. 1): S23-9. (Pubitemid 36395164)
9. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60. (Pubitemid 32729372)
10. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6. (Pubitemid 43374514)
11. Bratts R, Linden L,. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996; 10 (Suppl. 2): 81-90.
12. Hanauer SB, Stathopoulos G,. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 1991; 6: 192-219.
13. Lukert BP, Raisz LG,. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994; 20: 629-50. (Pubitemid 24271581)
14. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154: 97-101. (Pubitemid 24018107)
15. Whitworth JA,. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213-24. (Pubitemid 17069108)
16. Rutgeerts PJ,. The limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001; 15: 1515-25. (Pubitemid 32912394)
17. Stuck AE, Minder CE, Frey FJ,. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-63.
18. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
19. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009; 104: 1170-9.
20. Panaccione R, Rutgeerts P, Sandborn WJ, et al. Treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 674-88.
21. Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008; 27: 308-15.
22. Peyrin-Biroulet L, Laclotte C, Bigard MA,. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007; 25: 675-80.
23. Prefontaine E, Macdonald JK, Sutherland LR,. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010; 6: CD000545.
24. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; 1: CD000067.
25. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
26. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9. (Pubitemid 19259182)
27. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-32. (Pubitemid 30341531)
28. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-7.
29. Lowenberg M, Peppelenbosch M, Hommes D,. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs 2006; 66: 1431-9.
30. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
31. Lichtenstein GR, Thomsen OO, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010; 8: 600-9.
32. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38. (Pubitemid 47080387)
33. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50. (Pubitemid 47080388)
34. European Medicines Agency. Refusal Assessment Report For Cimzia. EMEA/176303/2008. Available at:. Published March 2008.
35. Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011; 17: 141-51.
36. Loftus EV, Pan X, Zurawski P, et al. Dosage pattern of adalimumab in real-world clinical practice and predictors of dosage increase in patients with Crohn's disease in the US. Gastroenterology 2009; 136: A175-6.
37. Pan X, Zurawski P, Mulani P, et al. Adalimumab dosage increase in Crohn's disease in specialty pharmacies (abstract). J Managed Care Pharm 2009; 15: 173.
38. Regueiro M, Siemanowski B, Kip K, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007; 13: 1093-9. (Pubitemid 47402592)
39. Wu EQ, Mulani P, Yu AP, et al. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. Value in Health 2008; 11: 820-9.
40. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009; 15: 1308-19.
41. Singleton JW, Law DH, Kelley ML Jr, et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 77: 870-82. (Pubitemid 9242049)
42. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
43. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36. (Pubitemid 351451967)
44. Sandborn W, Rutgeerts P, Reinisch W, et al. Sonic: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Am J Gastroenterol 2008; 103: S436.